[ad_1]
LiveHire was launched in 2012 with the goal of revolutionizing the recruitment industry. The company offers a marketplace of employees the opportunity to set up their resumes and skills on its technology platform, advertising their availability and suitability for various selected positions, rather than the usual method of employers posting job ads and potential employees working to secure a position.
Incidentally, this columnist used the LiveHire website and listed the position and desired parameters (such as income and preferred roster) to secure a mining production position at Gina Rinehart’s massive Roy Hill iron ore operation back in 2018. So, apparently, it works.
This week, the silver medal went to Artemis Resources, which wowed the market with the announcement of ultra-high-grade rock chip gold content exceeding 10,000 grams per tonne from its Titan gold prospect, part of the Karratha gold project.
Three of the company’s rock chip samples were too high in grade to be properly assayed by the lab, leading the lab to classify them as “out of limit” samples, which are classified as such when the gold content of a sample exceeds 1% (equivalent to 10 kg of gold per tonne).
Following the release of the test results, Artemis’ share price rose, soaring from 0.9 cents to a high of 1.7 cents, an increase of 88.89%, with a trading volume of 43.4 million shares on Thursday.
The samples collected from Titan are essentially considered a new discovery due to limited previous exploration work on the property. Titan is located adjacent to the company’s Carlow deposit, which has a JORC-compliant mineral resource of 374,000 ounces of gold.
To further add to the fun of finding high-grade gold in rock chip sampling, Artemis revealed that they took a 300kg bulk sample of the ore, which was then sorted, crushed, separated, and the gold was extracted. From the bulk sample, the company produced an astonishing 10.4oz gold bar, worth a whopping $38,625 in today’s local currency.
Artemis Resources has produced a stunning 10.4oz gold bar from sample material taken from the Titan prospect at its Karratha gold project.
To further “boost” Artemis’ share price, it was revealed that the assays also detected high-grade copper, with samples grading 23.8% and 14.55%.
That brings us to the bronze medal, which went to pharmaceutical development company LTR Pharma, which announced a co-development agreement with Aptar Pharma to advance the commercialization of its lead product, SPONTAN, in the U.S. and other key markets. SPONTAN is a rapidly absorbed, fast-acting erectile dysfunction medication that can help… um… improve the sexual health of men in a relationship.
The news sent the company’s share price… ahem, rising again… on a surge in trading volume, with 5.9 million shares traded on Tuesday, rising 75.61% from last week’s closing price of 82 cents to A$1.44.
LTR’s product is administered via nasal delivery technology, and a recent clinical trial showed that SPONTAN is absorbed faster and has a more rapid onset of action, but is equally effective, compared to well-known oral inhibitors such as sildenafil (Viagra), which belongs to the class of drugs called phosphodiesterase (PDE) inhibitors.
Aptar is considered a global leader in drug delivery systems and services, and has assisted many companies in obtaining approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for important combination drug device products using its nasal delivery systems.
LTR noted that since the successful trial, healthcare providers have begun prescribing SPONTAN locally, which has undoubtedly helped to put a big smile on many Australians’ faces.
Innovative cancer biotech Noxopharm narrowly missed the podium this week but still led the pack with a staggering gain of 64.47%. The company’s shares rose from 7.6c to 12.5c on Tuesday, with trading volumes far higher than normal at 6.4 million shares.
Noxopharm has announced encouraging new data for its preclinical drug “CRO-67” for the fight against pancreatic cancer, a disease that is particularly difficult to treat because tumors are surrounded by a dense cellular barrier that makes it difficult for anti-cancer drugs and the body’s own immune system to treat them.
Not to be upstaged by the Ultimate Fighting Championship (UFC), the world’s largest mixed martial arts promotion, which held its latest show in Western Australia, Noxopharm has unleashed its own ‘octagonal’ one-two punch in a bid to stamp out this insidious disease.
The new data, the result of ongoing collaborative research with a world-leading cancer team at UNSW Sydney, shows that CRO-67 significantly reduced tumour size and slowed tumour growth in mice – a double whammy for malignant cells.
In addition, the data showed that the drug was effective in a transplant model of pancreatic tumors in advanced human patients. In practical terms, this meant that the trial work involved transplanting human pancreatic cancer cells and barrier cells into the pancreases of mice.
Cell transplantation is beyond the scope of most studies because it involves more closely replicating human pancreatic cancer by growing human tumors and barrier cells surrounding the tumor site in mice, thereby mimicking the complex human tumor environment.
As one of the many who have lost loved ones to this terrible disease, I offer Noxopharm additional hope and wish them continued success in all their important trials.
Is your ASX listed company doing anything interesting? Contact details: mattbirney@bullsnbears.com.au
[ad_2]
Source link
